Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
CONCORD DRUGS TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CONCORD DRUGS Mar-23 |
TEVA PHARMA Dec-13 |
CONCORD DRUGS/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 42 | 3,481 | - | |
Low | Rs | 20 | 3,024 | - | |
Sales per share (Unadj.) | Rs | 55.9 | 1,997.6 | - | |
Earnings per share (Unadj.) | Rs | 1.1 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 2.8 | 286.3 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.24 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 33.4 | 2,219.0 | - | |
Shares outstanding (eoy) | m | 9.32 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.5 | 1.6 | 33.6% | |
Avg P/E ratio | x | 28.9 | 26.1 | 110.9% | |
P/CF ratio (eoy) | x | 10.9 | 11.4 | 96.0% | |
Price / Book Value ratio | x | 0.9 | 1.5 | 62.4% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 285 | 2,757,874 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 38 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,690.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 521 | 1,693,984 | 0.0% | |
Other income | Rs m | 0 | 0 | - | |
Total revenues | Rs m | 521 | 1,693,984 | 0.0% | |
Gross profit | Rs m | 46 | 463,899 | 0.0% | |
Depreciation | Rs m | 16 | 136,926 | 0.0% | |
Interest | Rs m | 17 | 33,273 | 0.1% | |
Profit before tax | Rs m | 12 | 293,700 | 0.0% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,798 | -0.0% | |
Tax | Rs m | 3 | -3,586 | -0.1% | |
Profit after tax | Rs m | 10 | 105,822 | 0.0% | |
Gross profit margin | % | 8.8 | 27.4 | 32.1% | |
Effective tax rate | % | 21.1 | -1.2 | -1,727.3% | |
Net profit margin | % | 1.9 | 6.2 | 30.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 435 | 1,144,111 | 0.0% | |
Current liabilities | Rs m | 216 | 997,761 | 0.0% | |
Net working cap to sales | % | 41.9 | 8.6 | 485.4% | |
Current ratio | x | 2.0 | 1.1 | 175.3% | |
Inventory Days | Days | 7 | 91 | 7.2% | |
Debtors Days | Days | 1,108 | 96 | 1,155.2% | |
Net fixed assets | Rs m | 148 | 553,293 | 0.0% | |
Share capital | Rs m | 93 | 4,170 | 2.2% | |
Net worth | Rs m | 311 | 1,881,695 | 0.0% | |
Long term debt | Rs m | 19 | 866,172 | 0.0% | |
Total assets | Rs m | 582 | 3,871,297 | 0.0% | |
Interest coverage | x | 1.7 | 9.8 | 17.6% | |
Debt to equity ratio | x | 0.1 | 0.5 | 13.3% | |
Sales to assets ratio | x | 0.9 | 0.4 | 204.4% | |
Return on assets | % | 4.6 | 3.6 | 128.7% | |
Return on equity | % | 3.2 | 5.6 | 56.3% | |
Return on capital | % | 8.9 | 4.9 | 181.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 17 | 269,933 | 0.0% | |
From Investments | Rs m | -23 | -95,648 | 0.0% | |
From Financial Activity | Rs m | 6 | -323,803 | -0.0% | |
Net Cashflow | Rs m | 0 | -149,518 | -0.0% |
Compare CONCORD DRUGS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare CONCORD DRUGS With: ADESHWAR MEDITEX VIVO BIO TECH PFIZER VAISHALI PHARMA AVON ORGANIC
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.